博茨瓦纳抗病毒治疗经历人群中隐球菌抗原血症的患病率与后遗症:反射性隐球菌抗原筛查评估
本研究在博茨瓦纳哈博罗内评估抗病毒治疗经历人群中反射性隐球菌抗原筛查的效用。2014-2016年收集CD4数据,2015年起对CD4≤100细胞/µL样本进行CrAg筛查。结果显示CrAg阳性率在门诊为4.8%、住院为21.9%,且与ART状态无关,但筛查时已接受ART的CrAg阳性者6个月死亡率显著更低,CrAg滴度≥1:80对6个月生存区分最佳。
要点
- CD4≤100细胞/µL者中门诊CrAg阳性率4.8%,住院21.9%。
- CrAg阳性率不因ART状态而异,但已接受ART者6个月死亡率更低。
- CrAg滴度≥1:80可识别6个月死亡高风险个体。
核心结论
- 抗病毒治疗经历人群中CrAg阳性率与未治疗人群相当。
- 重复筛查可发现CrAg血清转换者且存在隐球菌病风险。
- CrAg滴度≥1:80有助于识别死亡高风险个体以加强管理。
研究设计与样本
- 研究在博茨瓦纳哈博罗内评估反射性CrAg筛查的效用。
- 2014-2016年从HIV参考实验室收集CD4计数数据,2015年1月起对CD4≤100细胞/µL样本进行CrAg筛查。
- 共检测2108份CD4≤100细胞/µL样本,来自1645名独特患者,其中22%为重复样本。
主要发现
- 样本中40.9%(863)来自ART者,12.1%(255)为脱失者。
- 门诊CrAg患病率4.8%(72/1494;95% CI,3.8-6.0%),住院21.9%(32/151;95% CI,15.3-28.5%)。
- CrAg患病率不因ART状态而异,但筛查时已接受ART的CrAg阳性者6个月死亡率显著更低。
- 重复检测发现10例CrAg阳性者。
关键数值与推荐
- CrAg滴度 cutoff ≥1:80 对6个月生存提供最佳区分。
临床怎么用
- 对CD4≤100细胞/µL者进行反射性CrAg筛查,包括ART经历者。
- 考虑重复CrAg筛查以发现血清转换者。
- CrAg滴度≥1:80者应加强管理。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence to inform cryptococcal antigen (CrAg)-screening guidelines among ART-experienced populations is lacking. We performed a study evaluating the utility of reflex CrAg screening in Gaborone, Botswana. METHODS: CD4 count data were collected from the HIV reference laboratory from 2014-2016. CrAg screening was performed on samples with CD4 ≤100 cells/µL beginning January 2015. The proportion of CD4 counts ≤100 cells/µL was determined and the frequency of repeat CrAg testing described. Analyses ascertained the impact of ART status on CrAg prevalence and outcomes, and whether CrAg titers could be used for risk stratification. RESULTS: Overall, 5.6% (3335/59 300) of individuals tested had CD4 ≤100 cells/μL; 2108 samples with CD4 ≤100 cells/μL from 1645 unique patients were CrAg tested. Over half of samples were from ART-experienced individuals: 40.9% (863) on ART and 12.1% (255) defaulters; 22% (463) of CrAg tests were on repeat samples. CrAg prevalence was 4.8% (72/1494; 95% CI, 3.8-6.0%) among outpatients and 21.9% (32/151; 95% CI, 15.3-28.5%) among inpatients. CrAg prevalence rates did not differ by ART status, but 6-month mortality was significantly lower in CrAg-positive individuals on ART at screening. Ten CrAg positives were identified through repeat testing. A CrAg titer cutoff ≥1:80 provided the best discrimination for 6-month survival. CONCLUSIONS: CrAg-positivity rates in an ART-experienced population were comparable to those seen in ART-naive populations. Repeat screening identified individuals who seroconverted to CrAg positivity and were at risk of cryptococcal disease. CrAg titers ≥1:80 can help identify the individuals at highest risk of death for more intensive management.
引用
- Hurt WJ, Tenforde MW, Molefi M, et al. Prevalence and Sequelae of Cryptococcal Antigenemia in Antiretroviral Therapy-Experienced Populations: An Evaluation of Reflex Cryptococcal Antigen Screening in Botswana. Clin Infect Dis. 2021. PMID: 32236414. doi:10.1093/cid/ciaa356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。